Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Invested Capital: 2010-2025

Historic Invested Capital for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $950.2 million.

  • Ligand Pharmaceuticals' Invested Capital rose 12.96% to $950.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.2 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $830.5 million for FY2024, which is 18.49% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Invested Capital is $950.2 million, which was up 14.68% from $828.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Invested Capital's 5-year high stood at $950.2 million during Q3 2025, with a 5-year trough of $597.5 million in Q4 2022.
  • For the 3-year period, Ligand Pharmaceuticals' Invested Capital averaged around $780.4 million, with its median value being $795.5 million (2025).
  • Per our database at Business Quant, Ligand Pharmaceuticals' Invested Capital fell by 27.52% in 2023 and then increased by 25.94% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Invested Capital (Quarterly) stood at $821.3 million in 2021, then decreased by 27.24% to $597.5 million in 2022, then grew by 17.31% to $700.9 million in 2023, then climbed by 18.49% to $830.5 million in 2024, then increased by 12.96% to $950.2 million in 2025.
  • Its Invested Capital was $950.2 million in Q3 2025, compared to $828.5 million in Q2 2025 and $795.5 million in Q1 2025.